A B S T R A C T Hypertension and tachycardia are well known features of acute porphyria and have been shown to be related to increased circulating catecholamines. The mechanism by which circulating catecholamines are increased was studied using the isolated perfused rat heart and human platelets as a model of adrenergic neuronal function. It was found that neither 8-aminolevulinate (ALA) nor porphobilinogen (PBG) blocked uptake or caused release in the isolated perfused rat heart. Platelets from six patients with acute prophyria, three in remission and three latent, with matching normal controls were studied with regard to their uptake of [3H] 
INTRODUCTION
The hepatic porphyrias consist of acute intermittent porphyria (AIP),1 variegate porphyria, and hereditary coproporphyria (HC) . These three diseases share many common characteristics; they are transmitted as autosomal dominants, clinical exacerbations manifest themselves as similar episodes of acute neurological dysfunction, and acute episodes are associated with increased urinary excretion of 8-aminolevulinate (ALA) and porphobilinogen (PBG) (1) . The acute neurological exacerbations manifest themselves with tachycardia, hypertension, abdominal pain, constipation, vomiting, bladder symptoms, and ascending paralysis which may progress to quadriplegia and respiratory failure. The findings of tachycardia and hypertension have been frequently reported in AIP, and Waldenstrom considered the pulse rate to be a good indication of the activity of the disease (2) (3) (4) (5) (6) (7) (8) (9) (10) .
The pathogenesis of the hypertension and tachycardia in AIP has been studied by Schley et al. (7) , who studied four patients in the acute phase and in remission. They found significant correlations between blood pressure and pulse rate with the amount of catecholamine excretion. Atuk et al. confirmed these findings in three patients with acute porphyria (11) . The etiology of increased catecholamines is unclear. There are several possibilities which could account for the abnormalities: (a) increased release of norepinephrine (NE) and epinephrine due to pathologic changes within the sympathetic nervous system itself; (b) impaired metabolism of catecholamines; (c) impaired re-uptake of NE by the adrenergic neurons, or (d) some combination of the above mechanisms.
The present study was designed to investigate whether ALA or PBG, the two porphyrin precursors known to be elevated during acute attacks of acute porphyria, could either block neuronal catecholamine uptake or cause release of catecholamines. The isolated perfused rat heart was chosen because of its convenience for in vitro studies to determine whether ALA and PBG have a direct toxic effect on catecholamine metabolism. Studies were also performed on normal human platelets and platelets of patients with acute porphyria, because platelets are able to accumulate and store catecholamines by a process which resembles that of adrenergic neurons (12) (13) (14) (15) . The normal perfusion medium contained 119.8 mM NaCl, 5.63 mM KC1, 2.16 mM CaC12, 2.10 mM MgCl2, 100 mM dextrose, and 25 mM NaHCO3. The solution was bubbled with 95%02-5% CO2, and the temperature was maintained at 38±1°C, pH 7.32-7.45. All hearts were perfused at a constant flow of 6.0±1.0 ml/min with a Harvard perfusion pump (Harvard Apparatus Co., Inc., Millis, Mass.).
To test the influence of ALA and PBG on the uptake of NE, all hearts were equilibrated with normal medium for 30 min and then switched to a medium containing [3H]-norepinephrine ([3H]NE) (1.0 ng/ml of 1-[3H]NE, 3.8 Ci/mM sp. act.) with or without different concentrations of the compound to be studied. Hearts were perfused with the [3H]NEcontaining medium for 10 min, followed by 3 min of drugfree medium to wash out the extracellular space. 10 ng/ml ascorbic acid and 10 nglliter EDTA were added to the perfusion medium to prevent oxidation of NE. To inhibit monoamine oxidase, 0.125 mM pargyline was also added to the perfusion medium.
Hearts were removed at the end of the perfusion, weighed, and homogenized in 5% trichloroacetic acid. The homogenates were then filtered under suction, and a 1-ml aliquot was taken for analysis by liquid scintillation spectrometry. (15) . Each Amberlite eluate was adjusted to pH 8.4 with a 0.5-ml Tris buffer and passed over a 100-mg, 0.5-cm diameter, alumina column. The alumina columns were washed with 5 ml of 0.2 M sodium acetate, pH 8.4, and then with 5 ml ofwater containing 1% Triton X-100. [3H]NE was eluted with 1 ml of 0.2 N HC1. Eluates were collected directly into scintillation vials. For liquid scintillation counting, the 1-ml samples were placed in 10 ml of Triton-based solution containing 5.5 g of 2,5 diphenyloxazole, 150 mg of 1,4-bis-2-(5-phenyloxazolyl) benzene, and a 2:1 mixture of toluene and Triton X-100. The samples were then counted in a Packard Tri-carb liquid scintillation spectrophotometer (Packard Instrument Co., Inc., Downers Grove, Ill.). NE recoveries by Amberlite column were checked by passing known amounts of [3H]NE through parallel columns and found to be 81% with a range of 75-85%. Therefore, no correction for recovery has been made.
Release of [3H]NE. In these experiments, hearts from rats were connected to the perfusion apparatus as described above and perfused for 10 min with normal perfusion medium, and then for 20 min with 1.0 nglml of 1-[3H]NE, 3.8 Ci/mM sp act, in the perfusion medium to label the endogenous store. It was assumed that the release of [3H]NE from the heart reflects release from adrenergic terminals because procedures which cause degeneration of the nerve terminals, such as the use of 6-hydroxydopamine, are known to prevent drug-induced release of [3H]NE from the heart (17). After labeling with [3H]NE, the hearts were switched to a NE-free medium for 12 min. They were then perfused for 2 min with normal medium containing the compound to be tested via a side arm cannula and then switched back to a drug-free medium for another 10 min. The perfusate effluents from the hearts were continuously collected and analyzed for [3H]NE by liquid scintillation analysis after the suitable preparative procedures described above.
Platelet experiments. Six acute porphyria patients (three in remission and three latent) and six age-matched normotensive normal controls were selected for the study. Patients were characterized further by the determination of erythrocyte uroporphyrinogen I synthetase (URO-S) levels, as were the normal controls (18) . Platelet-rich plasma was prepared by collecting blood by venipuncture into plastic syringes containing 0.8 ml 19% wt/vol sodium citrate per each 10 ml of blood, to give a final concentration of 12.9 mM sodium citrate. Citrate was used as an anticoagulant, because Hughes and Brodie (19) have shown that EDTA impairs platelet uptake of serotonin and catecholamines. The citrated blood was then centrifuged three times for 10 min at 3000 rpm at room temperature with the platelet-rich plasma being pipetted off and pooled after each successive centrifugation. All glassware with which the platelets came into contact was made of plastic. Platelet counts were made by a light absorption particle analyzer. The platelet-rich plasma was then-pipetted in 1.8-ml aliquots into 15-ml conical plastic centrifuge tubes closed with a cap, through which a tube was thrust, and was gassed with 95% 02-5% CO2 mixture. The tubes were held in a water bath at 37°C and rocked gently to-and-fro mechanically. 28 tubes could be incubated simultaneously. After a 10-min incubation, 0.2 ml of a solution of NE in 0.9% sodium chloride solution with or without the drug being tested was added to each tube. The tubes were incubated for 90 min, then cooled in ice, and centrifuged at 10,000 rpm in a Sorvall #2 centrifuge (Du Pont Co., Instrument Products Div., Sorvall Biomedical Div., Wilmington, Del.) at 4°C for 10 min. The supernate was then poured off from the platelet pellet, and the tubes were left to drain for a few minutes. All adhering drops of plasma in the tubes were removed with filter paper. The pellets were then resuspended in 1 ml 5% TCA, frozen and thawed once to liberate the catecholamines, and recentrifuged for 10 min at 15,000 rpm. Following centrifugation, 0.8 ml of the supernate was added to 6 ml of liquid scintillator, and the radioactivity was counted in a Packard Tri-carb scintillation spectrometer. Inasmuch as the platelets were not washed after centrifugation, [3H]NE caught in the interstices of the platelet pellet was included in the estimation. Born and Bricknell (20) estimated that the volume of trapped solution was 0.352 1ul/108 platelets. It was calculated that this volume of radioactivity would make a negligible contribution to the total uptake radioactivity; therefore, no correction has been made for it.
The time-course of catecholamine uptake and accumulation in the platelets was linear over 90 min. Similarly, incubation with [3H]NE concentration (10 mM) was also linear over the same period (Fig. 1) , indicating that we were studying initial uptake. Using column chromatography, our studies on the metabolism of NE demonstrated that 70.5% of the total activity was represented by free 
The possibility that ALA and PBG might increase the release of NE from adrenergic neurons was examined next. Fig. 3 shows the effect of a 2-min application of KCl with ALA or PBG on the efflux of [3H]NE from rat hearts previously labeled with 3H-amine. KCl produced a marked increase in the release of [3H]NE (107% of the 6-min value). Neither ALA (A) nor PBG (B) in varying concentrations had any effect on the release of [3H]NE. Table I depicts the results of erythrocyte URO-S determinations. Five patients with AIP had low URO-S levels, a characteristic abnormality in this disease (21) , whereas all controls had normal values. The one patient with HC manifested a level of urinary coproporphyrin diagnostic of this disease during an acute exacerbation (22) (12) and found to produce a significant inhibition of [3H]NE uptake into platelets obtained from both groups.
DISCUSSION
The basic defect of AIP is a genetically determined partial lack of URO-S activity (21) . Thus, when ALA synthetase (the rate-controlling enzyme in the porphyrin pathway) is induced, the porphyrin precursors (ALA and PBG) build up to high levels in the blood. In HC, the enzymatic defect has recently been shown to be decreased activity of coproporphyrinogen oxidase. Substrate compensation for this defect is not possible, however, because the activity of URO-S becomes rate-limiting with consequent accumulation of PBG and ALA (22) . Since hematin feedback inhibits ALA synthetase, infusions of this compound have recently been used to treat acute attacks of AIP with successful clinical remission (23) . The elevated plasma levels of both ALA and PBG were shown to return (6) . The hypertension and tachycardia were found to correlate with the amount of catecholamine excretion (7, 11) . The etiology of elevated catecholamines has not been elucidated. Inasmuch as ALA and PBG are elevated during acute attacks and may be toxic, our studies were designed to examine whether either ALA or PGE could block uptake or cause release of catecholamines from adrenergic neurons.
The uptake of NE into isolated perfused rat hearts was studied first because this preparation has been well delineated as a model of sympathetic neuronal function (25) . Previous studies had demonstrated no tachycardia or hypertension in the presence of these compounds in experimental animals, but their effects on catecholamine metabolism had not been studied. The results demonstrate that neither ALA nor PBG in concentrations from 1 ,uM (23) .
Intact human platelets can be employed to test uptake mechanisms for NE (12) . The platelets are capable of functioning in appropriate conditions and actively taking up NE from the medium in concentrations up to 10 ,ug/liter (26). Our uptake experiments using this test system revealed that neither ALA nor PBG blocked uptake or [3H]NE in the platelets of normal controls. In contrast, both ALA and PBG significantly blocked the uptake of [3H]NE into the platelets ofpatients with acute porphyria. The patients' platelets were not deficient in uptake capacity, in that their control uptake of [3H]NE was actually greater than that of platelets from normal controls. The fact that PBG did not block uptake as well at the higher concentrations may have been due to its ability to polymerize in vitro to form porphyrins (5). There would be more of a tendency to polymerize at higher concentrations, and the products formed may have artifactually elevated [3H]NE uptake by causing membrane damage. Hematoporphyrin has been shown to be toxic to platelet membranes in vitro (27 (28, 29) . In nephrectomized rats receiving ALA or PBG intravenously, plasma concentrations of >5 mg/100 ml have been achieved without any alteration in blood pressure or symptoms of nervous system toxicity (23, 30) . Also, no alterations in blood pressure or heart rate have been observed in allylisopropylacetamideinduced experimental porphyria in rats (31) (32) (33) . The ingestion of 1 g ALA by a normal man was not associated with alteration of blood pressure or heart rate (34). All these observations are in accord with our findings that neither ALA nor PBG block uptake of [3H]NE in normal rat hearts and normal human platelets.
7In the past, both autonomic neuropathy and denervation of the baroreceptors have been proposed as underlying mechanisms for the tachycardia and hypertension seen during acute attacks of porphyria. Pathologic changes consisting primarily of demyelination have been described in the autonomic nervous system at autopsy (35, 36) . These changes, however, are probably secondary to a primary axonal metabolic disturbance as evidenced by normal nerve conduction velocities during acute attacks. The baroreceptor reflexes in one case of AIP were shown to be unresponsive to carotid sinus massage and procaine block (37) . This suggests a deafferentation of the baroreceptors which, in experimental situations, is known to lead to increased sympathetic tone by central neurogenic mechanisms (38) . The tachycardia and hypertension during acute attacks of porphyria may therefore be caused by several mechanisms. The finding of elevated catecholamines during acute attacks of porphyria has recently been brought to light. We found this to be the case in all of our patients.
The uptake of NE into human platelets has been proposed as a model of uptake into adrenergic neurons. The uptake mechanisms are similar in that they are temperature-dependent, saturable, and able to concentrate NE about five-fold. In addition, they are inhibited by the same drugs (12-14, 26, 39-41 (41) . Therefore, if there is decreased re-uptake of NE during acute attacks of porphyria, this must contribute to elevated levels of circulating catecholamines. It is therefore suggested that adrenergic-receptor blocking agents are the drugs ofchoice in managing the hypertension and tachycardia associated with acute porphyria. These have previously been shown to be effective, and they do not induce ALA synthetase in vitro (7, 11, 42) .
